Psychedelic therapies, including the use of MDMA, are set to revolutionize psychiatric treatments, especially for those with post-traumatic stress disorder (PTSD).
The anticipation builds for the FDA’s approval of MDMA-assisted therapy for PTSD, which will mark a first for a psychedelic drug in mainstream medicine. MDMA’s potential extends to patients with multiple or treatment-resistant disorders, particularly those who concurrently suffer from PTSD and substance use disorder (SUD).
Learn More: https://neurosciencenews.com/ptsd-psychedelics-23614/
